Russell J. Schilder - Concepedia

Author

Russell J. Schilder

Also Known As

R J Schilder, R SCHILDER, R Schilder, R. J. Schilder, R. Schilder, R.J. Schilder, Rudolph Schilder, Russell J. Schilder, Russell J Schilder, Russell J. Schilder

210

Publications

11.7K

Citations

H-Index

Concepts

All Affiliations

Fox Chase Cancer Center Roswell Park Comprehensive Cancer Center Thomas Jefferson University Gynecologic Oncology Group Memorial Sloan Kettering Cancer Center

About

Russell J. Schilder is an author at Fox Chase Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	67	4.7K
2	Health Sciences	8	8	1.2K
3	Biochemistry	3	3	226
4	Public Health	2	2	64
5	Engineering	1	1	56

Russell J. Schilder

Publications

10.1K

Citations

H-Index

Page 1

	Year	Citations
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma David G. Maloney, Antonio J Grillo-López, Christine A. White, Blood	1997	1.7K
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials David S. Hong, Steven G. DuBois, Shivaani Kummar, The Lancet Oncology Phase 1/2Surgical OncologyTumoral PathologyMedicineClinical Trials	2020	955
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20<sup>+</sup>B-Cell Non-Hodgkin's Lymphoma Thomas E. Witzig, Christine A. White, Gregory A. Wiseman, Journal of Clinical Oncology	1999	538
Focus on epithelial ovarian cancer Robert F. Ozols, Michael A. Bookman, Denise C. Connolly, Cancer Cell Epithelial Ovarian CancerMedicineGynecologyOncologyGynecology Oncology	2004	298
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Blood	2002	266
Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study Russell J. Schilder, Michael W. Sill, Xiaowei Chen, Clinical Cancer Research	2005	259
Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status Michael S. Gordon, Daniela Matei, Carol Aghajanian, Journal of Clinical Oncology	2006	249
RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model Seiji Mabuchi, Deborah A. Altomare, Mitchell Cheung, Clinical Cancer Research	2007	232
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, The Lancet Oncology MedicineGemcitabine Versus GemcitabineMetronomic TherapyGynecologyCancer Treatment	2020	227
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study Kian Behbakht, Michael W. Sill, Kathleen M. Darcy, Gynecologic Oncology Phase Ii TrialMedicineMetronomic TherapyGynecologyTumor Biomarkers	2011	203

Page 1